Therapeutic Monitoring and Prediction of the Efficacy of Neurotrophic Therapy in Patients with Amnestic-Type Mild Cognitive Decline Syndrome
Objectives. Therapeutic monitoring and evaluation of the efficacy of neurotrophic therapy in patients with amnestic-type mild cognitive decline syndrome (aMCI) were performed in a model using courses of cerebrolysin. Materials and methods. A total of 19 elderly patients meeting the diagnostic criteria for aMCI syndrome were studied. All patients received treatment with cerebrolysin: 20 intravenous dropwise infusions of 30 ml in 100 ml of physiological saline. Treatment efficacy was evaluated using psychometric tests and scales (CGI, MMSE, MoCA, MDRS, clock drawing test, BNT, 10-word memory test, 10-word delayed reproduction test, forward number naming test, backward number naming test) at study weeks 0, 4, 10, and 26. Levels of autoantibodies to p75 neurotrophin receptor were determined by solid-phase immnoenzyme analysis. Serum from 19 patients was studied before cerebrolysin treatment (day 0) and at weeks 10 and 26 after treatment initiation. Results and conclusions. Patients with aMCI had increased levels of autoantibodies to p75 fragment, with gradual decreases by 5.5 months of cerebrolysin treatment, indicating that this can potentially be used as a biomarker for long-term therapeutic efficacy. The modified p75 receptor fragment 155–164, assayed in patients’ serum, may provide an effective tool for monitoring and predicting the efficacy of long-term neurotrophic therapy.
Keywordselderly age mild cognitive decline dementia autoantibodies to p75 fragment neurotrophic therapy
Unable to display preview. Download preview PDF.
- 7.O. M. Volpina, N. I. Medvinskaya, A. V. Kamynina, et al., “Immunization with a synthetic fragment of the p75 neurotrophin receptor prevents loss of spatial memory and decreases β-amyloid levels in mice with experimentally induced Alzheimer’s disease,” Bioorgan. Khim., 40, No. 4, 451–457 (2014), https://doi.org/10.7868/S0132342314040150.Google Scholar
- 8.A. V. Sadin, N. Yu. Zhidomorov, I. V. Gogoleva, et al., “Studies of the neuroregenerative action of cerebrolysin in traumatic brain injury,” Zh. Nevrol. Psikhiat., 113, No. 4, 57–60 (2013).Google Scholar
- 10.H. S. Sharma, A. Sharma, H. Mossler, and D. F. Muresanu, “Neuroprotective effects of cerebrolysin, a combination of different active fragments of neurotrophic factors and peptides on the whole body hyperthermia-induced neurotoxicity: modulatory roles of co-morbidity factors and nanoparticle intoxication,” Int. Rev. Neurobiol., 102, 249–276 (2012), https://doi.org/10.1016/B978-0-12-386986-9.00010-7.Google Scholar
- 14.K. Ubhi, E. Rockenstein, R. Vazquez-Roque, et al., “cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease,” J. Neurosci. Res., 91, No. 2, 167–177 (2012), https://doi.org/10.1002/jnr.23142.Google Scholar
- 16.M. Reiner, M. Brunnbayer, A. Dunky, et al., “Therapeutic results with cerebrolysin in the treatment of dementia,” WMW Wien. Mod. Wochenschr., 147, 426–431 (1997).Google Scholar
- 17.E. Ruther, R. Ritter, M. Apecechea, et al., “Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer’s type,” Pharmacopsychiatry, 27, No. 1, 32–40 (1994).Google Scholar
- 18.S. I. Gavrilova, I. V. Kolykhalov, N. D. Selezneva, and G. A. Zharikov, “A double-blind, placebo-controlled study of the effects of cerebrolysin on the efficacy and tolerance of subsequent cholinergic therapy in patients with Alzheimer’s disease,” Zh. Sotsial. Klin. Psikhiatr., No. 2, 41–46 (2000).Google Scholar
- 19.N. P. Gerasimov, “A double-blind, placebo-controlled study of the efficacy of cerebrolysin in Alzheimer’s disease,” Sotsial. Klin. Psikhiatr., No. 2, 35–40 (2000).Google Scholar
- 21.S. I. Gavrilova, Pharmacotherapy of Alzheimer’s Disease, Pulse, Moscow (2007).Google Scholar
- 22.E. Rockenstein, K. Ubhi, E. Pham, et al., “Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer’s disease,” J. Neurosci. Res., 89, No. 11, 1812–1821 (2011), https://doi.org/10.1002/jnr.22712.Google Scholar
- 28.A. V. Kamynina, E. V. Ponomareva, D. O. Koroev, et al., “Decreased levels of antibodies to a fragment of the α7-type acetylcholine receptor in serum from patients with Alzheimer’s disease,” Zh. Nevrol. Psikhiat., 115, No. 12, 128–132 (2015).Google Scholar